Final Results from Phase 2 Combination Study of Kalydeco and VX-809 Show Significant Improvements
Source: Cystic Fibrosis Foundation A Phase 2 clinical trial of Kalydeco™ in combination with VX-809 showed significant improvements in lung function in people with the most common CF mutation, according to final results announced today by Vertex Pharmaceuticals Inc. Both Kalydeco and VX-809, a CF drug in...